Terminated PHASE2 INTERVENTIONAL 1-arm NCT00124579

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

S0417 A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma

Sponsor: National Cancer Institute (NCI)

Conditions Multiple Myeloma

Interventions bortezomib dexamethasone thalidomide

Updated 11 times since 2017 Last updated: Jul 13, 2018 Started: Aug 31, 2005 Primary completion: Jun 30, 2008 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

poor accrual

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

A PHASE2 clinical study on Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 11 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
May 2023 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2023 — May 2023 [monthly]

Terminated PHASE2

▶ Show 6 earlier versions

Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2
Sep 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Sep 2018 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alton, United States , American Fork, United States , Anderson, United States , Ann Arbor, United States , Battle Creek, United States , Beech Grove, United States , Bellingham, United States , Big Rapids, United States , Billings, United States , Bozeman, United States and 70 more locations